华兰生物：参股公司收到阿达木单抗注射液境内生产药品注册上市许可申请受理通知书

Core Viewpoint - The company Hualan Biological (002007.SZ) announced that its subsidiary, Hualan Ankang, received a notice of acceptance for the production registration application of Adalimumab injection from the National Medical Products Administration, indicating progress in the development of a biosimilar drug for various immune diseases [1] Group 1 - The drug Adalimumab is intended for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, and other immune-related diseases [1] - As of the announcement date, eight other companies in China have already received approval for their Adalimumab injections [1] - The acceptance notice for the drug will not impact the company's recent performance, as the timing and outcome of the registration approval remain uncertain [1]